Management of Rhinovirus and Enterovirus Infections

General Therapeutic Approach

• No antiviral agents are approved for routine treatment of rhinovirus or enterovirus infections; care should focus on supportive measures such as hydration, rest, and symptomatic relief. 1
• Supportive care remains the primary strategy for uncomplicated rhinovirus and enterovirus illnesses, which are typically self‑limiting. 2

Antibiotic Stewardship

• Antibiotics are ineffective against rhinovirus and enterovirus and should not be prescribed; despite this, 85–98 % of patients with clinically suspected rhinosinusitis receive antibiotics, reflecting widespread overuse. (Observational data) 3

Respiratory Complications in Specific Populations

• Rhinovirus infection is a major trigger for asthma exacerbations in both children and adults, necessitating close monitoring of asthmatic patients during viral upper‑respiratory episodes. (Epidemiologic evidence) 1

Management of Severe Enterovirus Disease

• For enterovirus encephalitis or other severe central‑nervous‑system involvement, no specific antiviral therapy is routinely recommended. (Expert consensus) [2][4]
• In severe cases, the investigational capsid‑binding agent pleconaril may be considered; phase‑III trials showed it shortened aseptic‑meningitis symptoms by roughly two days, although the drug is not widely available. (Moderate‑quality evidence) [2][4]
• Intravenous immunoglobulin (IVIG) has been employed for chronic enterovirus meningitis and severe enterovirus 71 infection, but no randomized controlled trials exist to confirm efficacy. (Low‑quality evidence) [2][4]
• Patients with decreasing level of consciousness from enteroviral CNS disease require immediate ICU evaluation for airway protection, ventilatory support, intracranial‑pressure management, cerebral‑perfusion optimization, and electrolyte correction. (Critical‑care guideline) [2][4]

Considerations for Immunocompromised Hosts

• Among allogeneic hematopoietic‑stem‑cell‑transplant (HSCT) recipients, rhinoviruses are the most frequently detected community‑acquired respiratory viruses, identified in up to 40 % of symptomatic patients. (Cohort study) 1
• Asymptomatic rhinovirus shedding occurs in approximately 13 % of HSCT patients, and prolonged shedding (>4 weeks) is common. (Cohort study) 1
• Lower‑respiratory‑tract disease with overt pneumonia is uncommon (<10 % of infected HSCT patients) but carries an estimated mortality of <10 %. (Observational data) 1
• In HSCT patients, lymphopenia (<500 cells/µL) is a risk factor for developing lower‑respiratory‑tract disease from enteroviruses. (Risk‑factor analysis) 1

Common Clinical Pitfalls (Evidence‑Based Alerts)

• Prescribing antibiotics based solely on colored nasal discharge is unwarranted; nasal discharge color reflects neutrophil presence rather than bacterial infection. (Evidence from clinical studies) [1][3]
• Persistence of symptoms beyond seven days does not reliably indicate bacterial infection; rhinovirus illnesses often last 10–15 days, with 7–13 % of cases extending to 15 days. (Prospective symptom‑duration data) [1][3]

Treatment Approach for Rhinovirus and Enterovirus Infections

Diagnostic Considerations

• The American Academy of Pediatrics and the Centers for Disease Control and Prevention recommend reverse transcriptase PCR (RT-PCR) targeting the 5′non-coding region (5′NCR) as the diagnostic method for enterovirus and rhinovirus infections due to its sensitivity, specificity, and short turnaround time 5, 6
• Multiple samples, including respiratory specimens, stool samples, cerebrospinal fluid (CSF), and blood samples, should be collected for optimal detection, depending on clinical presentation 7, 8
• Respiratory specimens are particularly important for detecting EV-D68, which is rarely found in CSF or stool samples 6, 8
• Virus isolation should not be used for routine diagnosis but can be helpful for further characterization 5, 6
• Serological methods such as ELISA and neutralization tests are not recommended for diagnosis of acute EV infection 5, 6

Supportive Treatment for Uncomplicated Infections

• The American College of Physicians recommends adequate hydration to fluidify secretions 9
• Nasal saline irrigation is recommended to relieve congestion and facilitate clearance of secretions 9
• Antipyretics/analgesics, such as acetaminophen or NSAIDs, are recommended for fever and pain relief 9
• Rest is recommended to promote recovery 9
• Humidification of the environment is recommended to alleviate mucosal dryness 9

Pharmacological Management

• First-generation antihistamine/decongestant combinations may help reduce cough and other symptoms 9
• Newer generation non-sedating antihistamines are relatively ineffective for common cold symptoms 9
• Oral decongestants may provide symptomatic relief but consider contraindications like hypertension 9
• Topical nasal decongestants should be limited to short periods (3-5 days) to avoid rebound congestion 9
• The Infectious Diseases Society of America recommends that antibiotics are not used for uncomplicated rhinovirus or enterovirus infections as they are ineffective against viruses and contribute to antimicrobial resistance 9

Special Considerations

• Immunocompromised patients may experience prolonged viral shedding and more severe disease 10
• The American Academy of Pediatrics recommends avoiding decongestants and antihistamines in children under 3 years due to potential adverse effects 9
• Patients with underlying conditions like asthma should be monitored closely, as rhinovirus is a common trigger for exacerbations 10

Infection Control Measures

• The Centers for Disease Control and Prevention recommend standard and contact precautions to prevent transmission in healthcare settings 7, 10
• Hand hygiene is crucial as these viruses can spread through direct contact with respiratory secretions 10
• Patients should be educated about covering coughs and sneezes and proper disposal of tissues 9

Management of Enterovirus Meningitis

General Supportive Care

• Routine enterovirus meningitis is managed with supportive care alone; no specific antiviral therapy is recommended for uncomplicated cases. 11
• The illness is self‑limited, typically resolving within 7–10 days while symptomatic treatment is provided. 12
• Patients should be advised to rest and avoid immediate return to full activities; fatigue and sleep disturbances are common for several weeks after discharge. 11

Antibiotic Stewardship

• Antibiotics should be discontinued promptly once enterovirus infection is confirmed by cerebrospinal fluid (CSF) PCR, which reduces unnecessary investigations and shortens hospital stay. 12

Antiviral Considerations

• Pleconaril may be used in severe enterovirus meningitis, although it is not widely available. 13
• In phase‑III trials, pleconaril shortened headache duration by approximately 2 days compared with placebo in patients with aseptic meningitis. 13
• Intravenous immunoglobulin (IVIG) can be considered for severe Enterovirus 71 infection or chronic meningitis, particularly in immunocompromised individuals; no randomized controlled trials support this practice. 13

Critical Care Assessment

• Patients who develop a declining level of consciousness require immediate intensive‑care evaluation for airway protection, ventilatory support, management of raised intracranial pressure, optimization of cerebral perfusion pressure, and correction of electrolyte disturbances. 13
• Altered consciousness more often indicates encephalitis or bacterial meningitis rather than uncomplicated viral meningitis. 11

Diagnostic Confirmation

• CSF PCR is the gold‑standard test for confirming enterovirus meningitis, with results ideally available within 24–48 hours. 12
• Diagnostic panels should include PCR for enteroviruses, HSV‑1, HSV‑2, and VZV in the CSF. 11
• Adding throat and rectal swabs for enterovirus PCR increases overall diagnostic yield. 12
• A definitive pathogen is not identified in 30–50 % of cases initially presumed to be viral meningitis. 11

Common Pitfalls to Avoid

• Acyclovir or valacyclovir should not be prescribed for enterovirus meningitis; these agents are only effective against HSV/VZV. 12
• Continuation of antibiotics while awaiting PCR results is unnecessary when clinical and CSF findings (lymphocytic pleocytosis, normal glucose, mildly elevated protein) strongly suggest a viral etiology. 11
• Discharge without counseling on expected recovery is discouraged; more than 50 % of patients experience headaches lasting >1 week, and fatigue or emotional difficulties may persist for weeks to months. 12

Post‑Discharge Management

• All patients with confirmed viral meningitis should receive scheduled follow‑up care. 11
• Return to work or study should be staged, beginning with part‑time activity. 12
• Clinicians should proactively address fatigue, sleep disturbances, and emotional difficulties, with early mental‑health referral when needed. 11

Special Populations

• Immunocompromised individuals may require prolonged monitoring and consideration of IVIG because they can have extended viral shedding and more severe disease courses. 13